000300648 001__ 300648
000300648 005__ 20250829084522.0
000300648 0247_ $$2doi$$a10.1182/bloodadvances.2024015732
000300648 0247_ $$2pmid$$apmid:40267180
000300648 0247_ $$2ISSN$$a2473-9529
000300648 0247_ $$2ISSN$$a2473-9537
000300648 0247_ $$2altmetric$$aaltmetric:176418563
000300648 037__ $$aDKFZ-2025-00859
000300648 041__ $$aEnglish
000300648 082__ $$a610
000300648 1001_ $$aFrenking, Jan Hendrik$$b0
000300648 245__ $$aBridging intensity is associated with impaired hematopoietic recovery following BCMA CAR-T therapy for multiple myeloma.
000300648 260__ $$aWashington, DC$$bAmerican Society of Hematology$$c2025
000300648 3367_ $$2DRIVER$$aarticle
000300648 3367_ $$2DataCite$$aOutput Types/Journal article
000300648 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1756449811_12785
000300648 3367_ $$2BibTeX$$aARTICLE
000300648 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000300648 3367_ $$00$$2EndNote$$aJournal Article
000300648 500__ $$a2025 Aug 26;9(16):4151-4166
000300648 520__ $$aChimeric antigen receptor (CAR) T-cell therapy represents a major advance in the treatment of relapsed/refractory multiple myeloma (RRMM). However, the long time span from leukapheresis to actual CAR T-cell infusion often necessitates bridging therapies. Due to limited knowledge about the effects of bridging on post-CAR-T clinical course and outcomes, the selection of treatment options is challenging. In this multicenter international observational study, we explored the impact of bridging therapy on hematopoietic reconstitution in 158 patients with RRMM treated with B-cell maturation antigen (BCMA)-directed CAR T-cell therapy. Based on exposure to classical cytotoxic (CTX) chemotherapy, we classified bridging regimens as non-CTX, intermediate CTX (1-2 CTX agents) or intensive CTX (≥ 3 CTX agents or high-dose therapy with stem cell transplantation). We found associations between the number of cytotoxic agents used and impaired post-CAR-T hematopoietic reconstitution, evident across hematopoietic cell lineages and particularly manifesting during the late post-CAR-T period. Intensive CTX bridging was associated with a prolonged time to neutrophil and platelet recovery, distinct patterns of hematopoietic recovery (e.g., an intermittent phenotype characterized by a second drop), an increased susceptibility to severe infections and a significantly increased risk for severe late cytopenias in uni- and multivariate models. Taken together, these results highlight that bridging intensity distinctly shapes the trajectory of hematopoietic recovery after BCMA CAR-T. Targeted and novel immunotherapies could provide alternatives for bridging, and high-risk patients may particularly benefit from enhanced monitoring, prophylaxis and supportive care.
000300648 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000300648 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000300648 7001_ $$aZhou, Xiang$$b1
000300648 7001_ $$aRejeski, Kai$$b2
000300648 7001_ $$aWagner, Vivien$$b3
000300648 7001_ $$aCostello, Patrick$$b4
000300648 7001_ $$0P:(DE-He78)743a4a82daab55306a2c88b9f6bf8c2f$$aHielscher, Thomas$$b5$$udkfz
000300648 7001_ $$aGatti, Lilan$$b6
000300648 7001_ $$aKauer, Joseph$$b7
000300648 7001_ $$aNadeem, Omar$$b8
000300648 7001_ $$00000-0002-6226-1252$$aMai, Elias K$$b9
000300648 7001_ $$00009-0004-1596-3763$$aMichel, Christian S$$b10
000300648 7001_ $$aFriedrich, Mirco J$$b11
000300648 7001_ $$aSedloev, David Nikolov$$b12
000300648 7001_ $$aWeinhold, Niels$$b13
000300648 7001_ $$aGoldschmidt, Hartmut$$b14
000300648 7001_ $$aHerfarth, Klaus$$b15
000300648 7001_ $$aSchmitt, Anita$$b16
000300648 7001_ $$aHundemer, Michael$$b17
000300648 7001_ $$aSchmitt, Michael$$b18
000300648 7001_ $$aMüller-Tidow, Carsten$$b19
000300648 7001_ $$aTopp, Max S$$b20
000300648 7001_ $$aEinsele, Hermann$$b21
000300648 7001_ $$aDreger, Peter$$b22
000300648 7001_ $$aMunshi, Nikhil C$$b23
000300648 7001_ $$00000-0002-9369-4413$$aSperling, Adam S$$b24
000300648 7001_ $$00000-0002-9536-9649$$aRasche, Leo$$b25
000300648 7001_ $$aSauer, Sandra$$b26
000300648 7001_ $$aRaab, Marc S$$b27
000300648 773__ $$0PERI:(DE-600)2876449-3$$a10.1182/bloodadvances.2024015732$$gp. bloodadvances.2024015732$$n16$$p4151-4166$$tBlood advances$$v9$$x2473-9529$$y2025
000300648 909CO $$ooai:inrepo02.dkfz.de:300648$$pVDB
000300648 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)743a4a82daab55306a2c88b9f6bf8c2f$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000300648 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000300648 9141_ $$y2025
000300648 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bBLOOD ADV : 2022$$d2024-12-16
000300648 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-16
000300648 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-16
000300648 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2024-07-05T12:07:28Z
000300648 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2024-07-05T12:07:28Z
000300648 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Anonymous peer review$$d2024-07-05T12:07:28Z
000300648 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-16
000300648 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2024-12-16
000300648 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-16
000300648 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2024-12-16
000300648 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2024-12-16
000300648 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2024-12-16
000300648 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-16
000300648 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-16
000300648 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bBLOOD ADV : 2022$$d2024-12-16
000300648 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2024-12-16
000300648 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2024-12-16
000300648 9201_ $$0I:(DE-He78)C060-20160331$$kC060$$lC060 Biostatistik$$x0
000300648 980__ $$ajournal
000300648 980__ $$aVDB
000300648 980__ $$aI:(DE-He78)C060-20160331
000300648 980__ $$aUNRESTRICTED